Cavatak (gebasaxturev) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   198 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cavatak (gebasaxturev) / Merck (MSD)
NCT04152863 / 2019-002034-36: Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Terminated
2
85
Europe, US, RoW
Gebasaxturev IV, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, Gebasaxturev ITu, Pembrolizumab, MK-3475, Keytruda®
Merck Sharp & Dohme LLC
Advanced/Metastatic Melanoma
07/23
07/23
2019-003978-22: Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL Sottostudio di fase 1/2 sui trattamenti oncologici neoadiuvanti per il melanoma

Not yet recruiting
1/2
65
Europe
PEMBROLIZUMAB, -, CVA21, [MK-3475], [-], [MK-7684], [V937], Solution for infusion, Solution for injection, KEYTRUDA (pembrolizumab, MK-3475)
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma Melanoma, Melanoma Melanoma, Diseases [C] - Cancer [C04]
 
 
NCT02824965: Pembrolizumab + CVA21 in Advanced NSCLC

Checkmark From KEYNOTE-200 study in combination with CVA21 for NSCLC and bladder cancer [screenshot]
Nov 2017 - Nov 2017: From KEYNOTE-200 study in combination with CVA21 for NSCLC and bladder cancer [screenshot]
Active, not recruiting
1/2
11
RoW
Pembrolizumab, KEYTRUDA, CVA21, CAVATAK, Coxsackie virus 21
Olivia Newton-John Cancer Research Institute, Merck Sharp & Dohme LLC, Viralytics
Non-Small Cell Lung Cancer
07/21
10/21
NCT04521621 / 2020-001908-42: A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

Terminated
1/2
76
Europe, Canada, Japan, US, RoW
Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC
Neoplasm Metastasis
07/23
07/23
KEYMAKER-U02 Substudy 02C, NCT04303169: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Active, not recruiting
1/2
90
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, MK-4830, Favezelimab + Pembrolizumab, MK-4280A, ATRA, Tretinoin, Vesanoid®
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30

Download Options